{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:49:55Z","timestamp":1777884595894,"version":"3.51.4"},"reference-count":9,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:00:00Z","timestamp":1654300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Technology"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:p>Background: Direct-acting antiviral (DAA) agents have revolutionized the treatment of chronic hepatitis C virus (HCV) infection. Current data regarding the utility of on-treatment HCV viral load (VL) monitoring are conflicting and limited data are available in HIV-coinfected patients. Objective: The objective of the study was to determine whether on-treatment VLs are predictive of HCV cure in a real-world population. Method: A single-center, retrospective cohort study was conducted using patients who received a prescription for DAA therapy for HCV treatment at a large, tertiary ambulatory care clinic. Results: A total of 219 patients were included in the final analysis. The average age was 56 years. Most patients were male (64.4%), African American (73.1%), and insured by Medicaid (61.6%). Most patients were treatment-naive, noncirrhotic, and infected with HCV genotype 1a (73.1%). About 22.4% of patients were coinfected with HIV. The most common regimen was 12 weeks of ledipasvir\/sofosbuvir (53.9%). On-treatment VLs were most commonly obtained at treatment week 4 (42.5%), of which 45.2% of patients were detectable. Sustained virologic response (SVR) was achieved in 96.8% of the total population and 95.9% of HIV-coinfected patients. Of the 7 patients who did not achieve SVR, 3 patients had undetectable on-treatment VLs in the first 8 weeks of therapy. Conclusion: Sustained virologic response rates were similar between HCV-monoinfected patients and HCV-HIV-coinfected patients. This research further supports that on-treatment VLs may not be a valuable indicator of treatment failure but may be helpful to engage patients in care and ensure treatment adherence and ultimately cure.<\/jats:p>","DOI":"10.1177\/87551225221092598","type":"journal-article","created":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T06:21:22Z","timestamp":1654323682000},"page":"213-217","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Utility of On-Treatment Viral Loads During Treatment With Direct-Acting Antivirals in Patients Infected With Chronic Viral Hepatitis C"],"prefix":"10.1177","volume":"38","author":[{"given":"Shila","family":"Mortazavi","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2932-3327","authenticated-orcid":false,"given":"Lauren M.","family":"Hynicka","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,6,4]]},"reference":[{"key":"bibr1-87551225221092598","unstructured":"Hepatitis C questions and answers for health professionals. Accessed July 13, 2021. https:\/\/www.cdc.gov\/hepatitis\/hcv\/hcvfaq.htm#section1."},{"key":"bibr2-87551225221092598","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.07.013"},{"key":"bibr3-87551225221092598","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.04.015"},{"key":"bibr4-87551225221092598","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ170"},{"key":"bibr5-87551225221092598","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-016-9725-6"},{"key":"bibr6-87551225221092598","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12731"},{"key":"bibr7-87551225221092598","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020921166"},{"key":"bibr8-87551225221092598","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa219"},{"key":"bibr9-87551225221092598","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74568-x"}],"container-title":["Journal of Pharmacy Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225221092598","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/87551225221092598","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225221092598","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:30:58Z","timestamp":1777602658000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/87551225221092598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,4]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1177\/87551225221092598"],"URL":"https:\/\/doi.org\/10.1177\/87551225221092598","relation":{},"ISSN":["8755-1225","1549-4810"],"issn-type":[{"value":"8755-1225","type":"print"},{"value":"1549-4810","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,4]]}}}